- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Hepatitis B Vaccine (Recombinant) will have significant change from previous year. By the most conservative estimates of global Hepatitis B Vaccine (Recombinant) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Hepatitis B Vaccine (Recombinant) market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis B Vaccine (Recombinant) market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Hepatitis B Vaccine (Recombinant), covering the supply chain analysis, impact assessment to the Hepatitis B Vaccine (Recombinant) market size growth rate in several scenarios, and the measures to be undertaken by Hepatitis B Vaccine (Recombinant) companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
10mcg/0.5ml
10mcg/ml
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Newborn
Adult
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
GSK
Merck
Dynavax Technologies
LG Life Sciences
Sanofi Pasteur
Serum Institute
KM Biologics
Shenzhen Kangtai Biological Products
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Hepatitis B Vaccine (Recombinant) consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Hepatitis B Vaccine (Recombinant) market by identifying its various subsegments.
Focuses on the key global Hepatitis B Vaccine (Recombinant) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hepatitis B Vaccine (Recombinant) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hepatitis B Vaccine (Recombinant) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Hepatitis B Vaccine (Recombinant)?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Hepatitis B Vaccine (Recombinant) Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hepatitis B Vaccine (Recombinant) Consumption 2015-2025
2.1.2 Hepatitis B Vaccine (Recombinant) Consumption CAGR by Region
2.2 Hepatitis B Vaccine (Recombinant) Segment by Type
2.2.1 10mcg/0.5ml
2.2.2 10mcg/ml
2.3 Hepatitis B Vaccine (Recombinant) Consumption by Type
2.3.1 Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
2.3.2 Global Hepatitis B Vaccine (Recombinant) Revenue and Market Share by Type (2015-2020)
2.3.3 Global Hepatitis B Vaccine (Recombinant) Sale Price by Type (2015-2020)
2.4 Hepatitis B Vaccine (Recombinant) Segment by Application
2.4.1 Newborn
2.4.2 Adult
2.5 Hepatitis B Vaccine (Recombinant) Consumption by Application
2.5.1 Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
2.5.2 Global Hepatitis B Vaccine (Recombinant) Value and Market Share by Type (2015-2020)
2.5.3 Global Hepatitis B Vaccine (Recombinant) Sale Price by Type (2015-2020)
3 Global Hepatitis B Vaccine (Recombinant) by Company
3.1 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Company
3.1.1 Global Hepatitis B Vaccine (Recombinant) Sales by Company (2018-2020)
3.1.2 Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Company (2018-2020)
3.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company
3.2.1 Global Hepatitis B Vaccine (Recombinant) Revenue by Company (2018-2020)
3.2.2 Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company (2018-2020)
3.3 Global Hepatitis B Vaccine (Recombinant) Sale Price by Company
3.4 Global Hepatitis B Vaccine (Recombinant) Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Hepatitis B Vaccine (Recombinant) Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Hepatitis B Vaccine (Recombinant) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Hepatitis B Vaccine (Recombinant) by Regions
4.1 Hepatitis B Vaccine (Recombinant) by Regions
4.2 Americas Hepatitis B Vaccine (Recombinant) Consumption Growth
4.3 APAC Hepatitis B Vaccine (Recombinant) Consumption Growth
4.4 Europe Hepatitis B Vaccine (Recombinant) Consumption Growth
4.5 Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Growth
5 Americas
5.1 Americas Hepatitis B Vaccine (Recombinant) Consumption by Countries
5.1.1 Americas Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020)
5.1.2 Americas Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020)
5.2 Americas Hepatitis B Vaccine (Recombinant) Consumption by Type
5.3 Americas Hepatitis B Vaccine (Recombinant) Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Hepatitis B Vaccine (Recombinant) Consumption by Regions
6.1.1 APAC Hepatitis B Vaccine (Recombinant) Consumption by Regions (2015-2020)
6.1.2 APAC Hepatitis B Vaccine (Recombinant) Value by Regions (2015-2020)
6.2 APAC Hepatitis B Vaccine (Recombinant) Consumption by Type
6.3 APAC Hepatitis B Vaccine (Recombinant) Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Hepatitis B Vaccine (Recombinant) by Countries
7.1.1 Europe Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020)
7.1.2 Europe Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020)
7.2 Europe Hepatitis B Vaccine (Recombinant) Consumption by Type
7.3 Europe Hepatitis B Vaccine (Recombinant) Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Hepatitis B Vaccine (Recombinant) by Countries
8.1.1 Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020)
8.2 Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Type
8.3 Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Hepatitis B Vaccine (Recombinant) Distributors
10.3 Hepatitis B Vaccine (Recombinant) Customer
11 Global Hepatitis B Vaccine (Recombinant) Market Forecast
11.1 Global Hepatitis B Vaccine (Recombinant) Consumption Forecast (2021-2025)
11.2 Global Hepatitis B Vaccine (Recombinant) Forecast by Regions
11.2.1 Global Hepatitis B Vaccine (Recombinant) Forecast by Regions (2021-2025)
11.2.2 Global Hepatitis B Vaccine (Recombinant) Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Hepatitis B Vaccine (Recombinant) Forecast by Type
11.8 Global Hepatitis B Vaccine (Recombinant) Forecast by Application
12 Key Players Analysis
12.1 GSK
12.1.1 Company Information
12.1.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 GSK Latest Developments
12.2 Merck
12.2.1 Company Information
12.2.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.2.3 Merck Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Merck Latest Developments
12.3 Dynavax Technologies
12.3.1 Company Information
12.3.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.3.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Dynavax Technologies Latest Developments
12.4 LG Life Sciences
12.4.1 Company Information
12.4.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.4.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 LG Life Sciences Latest Developments
12.5 Sanofi Pasteur
12.5.1 Company Information
12.5.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.5.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Sanofi Pasteur Latest Developments
12.6 Serum Institute
12.6.1 Company Information
12.6.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.6.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Serum Institute Latest Developments
12.7 KM Biologics
12.7.1 Company Information
12.7.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 KM Biologics Latest Developments
12.8 Shenzhen Kangtai Biological Products
12.8.1 Company Information
12.8.2 Hepatitis B Vaccine (Recombinant) Product Offered
12.8.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Shenzhen Kangtai Biological Products Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Hepatitis B Vaccine (Recombinant) Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Hepatitis B Vaccine (Recombinant) Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Hepatitis B Vaccine (Recombinant) Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of 10mcg/0.5ml
Table 7. Major Players of 10mcg/ml
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Table 10. Global Hepatitis B Vaccine (Recombinant) Revenue by Type (2015-2020) ($ million)
Table 11. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Hepatitis B Vaccine (Recombinant) Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Table 15. Global Hepatitis B Vaccine (Recombinant) Value by Application (2015-2020)
Table 16. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Application (2015-2020)
Table 17. Global Hepatitis B Vaccine (Recombinant) Sale Price by Application (2015-2020)
Table 18. Global Hepatitis B Vaccine (Recombinant) Sales by Company (2017-2019) (K Units)
Table 19. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Company (2017-2019)
Table 20. Global Hepatitis B Vaccine (Recombinant) Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company (2017-2019)
Table 22. Global Hepatitis B Vaccine (Recombinant) Sale Price by Company (2017-2019)
Table 23. Global Hepatitis B Vaccine (Recombinant) Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Hepatitis B Vaccine (Recombinant) Products Offered
Table 25. Hepatitis B Vaccine (Recombinant) Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Hepatitis B Vaccine (Recombinant) Consumption by Regions 2015-2020 (K Units)
Table 27. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Regions 2015-2020
Table 28. Global Hepatitis B Vaccine (Recombinant) Value by Regions 2015-2020 ($ Millions)
Table 29. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Regions 2015-2020
Table 30. Americas Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020) (K Units)
Table 31. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries (2015-2020)
Table 32. Americas Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Hepatitis B Vaccine (Recombinant) Value Market Share by Countries (2015-2020)
Table 34. Americas Hepatitis B Vaccine (Recombinant) Consumption by Type (2015-2020) (K Units)
Table 35. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Table 36. Americas Hepatitis B Vaccine (Recombinant) Consumption by Application (2015-2020) (K Units)
Table 37. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Table 38. APAC Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020) (K Units)
Table 39. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries (2015-2020)
Table 40. APAC Hepatitis B Vaccine (Recombinant) Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Hepatitis B Vaccine (Recombinant) Value Market Share by Regions (2015-2020)
Table 42. APAC Hepatitis B Vaccine (Recombinant) Consumption by Type (2015-2020) (K Units)
Table 43. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Table 44. APAC Hepatitis B Vaccine (Recombinant) Consumption by Application (2015-2020) (K Units)
Table 45. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Table 46. Europe Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020) (K Units)
Table 47. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries (2015-2020)
Table 48. Europe Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Hepatitis B Vaccine (Recombinant) Value Market Share by Countries (2015-2020)
Table 50. Europe Hepatitis B Vaccine (Recombinant) Consumption by Type (2015-2020) (K Units)
Table 51. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Table 52. Europe Hepatitis B Vaccine (Recombinant) Consumption by Application (2015-2020) (K Units)
Table 53. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Countries (2015-2020) (K Units)
Table 55. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Hepatitis B Vaccine (Recombinant) Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Hepatitis B Vaccine (Recombinant) Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Type (2015-2020) (K Units)
Table 59. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption by Application (2015-2020) (K Units)
Table 61. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Table 62. Hepatitis B Vaccine (Recombinant) Distributors List
Table 63. Hepatitis B Vaccine (Recombinant) Customer List
Table 64. Global Hepatitis B Vaccine (Recombinant) Consumption Forecast by Countries (2021-2025) (K Units)
Table 65. Global Hepatitis B Vaccine (Recombinant) Consumption Market Forecast by Regions
Table 66. Global Hepatitis B Vaccine (Recombinant) Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Hepatitis B Vaccine (Recombinant) Value Market Share Forecast by Regions
Table 68. Global Hepatitis B Vaccine (Recombinant) Consumption Forecast by Type (2021-2025) (K Units)
Table 69. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Hepatitis B Vaccine (Recombinant) Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Hepatitis B Vaccine (Recombinant) Value Market Share Forecast by Type (2021-2025)
Table 72. Global Hepatitis B Vaccine (Recombinant) Consumption Forecast by Application (2021-2025) (K Units)
Table 73. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Hepatitis B Vaccine (Recombinant) Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Hepatitis B Vaccine (Recombinant) Value Market Share Forecast by Application (2021-2025)
Table 76. GSK Product Offered
Table 77. GSK Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 78. GSK Main Business
Table 79. GSK Latest Developments
Table 80. GSK Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 81. Merck Product Offered
Table 82. Merck Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 83. Merck Main Business
Table 84. Merck Latest Developments
Table 85. Merck Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 86. Dynavax Technologies Product Offered
Table 87. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 88. Dynavax Technologies Main Business
Table 89. Dynavax Technologies Latest Developments
Table 90. Dynavax Technologies Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 91. LG Life Sciences Product Offered
Table 92. LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 93. LG Life Sciences Main Business
Table 94. LG Life Sciences Latest Developments
Table 95. LG Life Sciences Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 96. Sanofi Pasteur Product Offered
Table 97. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 98. Sanofi Pasteur Main Business
Table 99. Sanofi Pasteur Latest Developments
Table 100. Sanofi Pasteur Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 101. Serum Institute Product Offered
Table 102. Serum Institute Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 103. Serum Institute Main Business
Table 104. Serum Institute Latest Developments
Table 105. Serum Institute Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 106. KM Biologics Product Offered
Table 107. KM Biologics Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
Table 108. KM Biologics Main Business
Table 109. KM Biologics Latest Developments
Table 110. KM Biologics Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 111. Shenzhen Kangtai Biological Products Product Offered
Table 112. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 113. Shenzhen Kangtai Biological Products Main Business
Table 114. Shenzhen Kangtai Biological Products Latest Developments
Table 115. Shenzhen Kangtai Biological Products Basic Information, Company Total Revenue (in $ million), Hepatitis B Vaccine (Recombinant) Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Hepatitis B Vaccine (Recombinant)
Figure 2. Hepatitis B Vaccine (Recombinant) Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Hepatitis B Vaccine (Recombinant) Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Hepatitis B Vaccine (Recombinant) Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of 10mcg/0.5ml
Figure 7. Product Picture of 10mcg/ml
Figure 8. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type (2015-2020)
Figure 9. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Type (2015-2020)
Figure 10. Hepatitis B Vaccine (Recombinant) Consumed in Newborn
Figure 11. Global Hepatitis B Vaccine (Recombinant) Market: Newborn (2015-2020) (K Units)
Figure 12. Global Hepatitis B Vaccine (Recombinant) Market: Newborn (2015-2020) ($ Millions)
Figure 13. Hepatitis B Vaccine (Recombinant) Consumed in Adult
Figure 14. Global Hepatitis B Vaccine (Recombinant) Market: Adult (2015-2020) (K Units)
Figure 15. Global Hepatitis B Vaccine (Recombinant) Market: Adult (2015-2020) ($ Millions)
Figure 16. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application (2015-2020)
Figure 17. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Application (2015-2020)
Figure 18. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Company in 2017
Figure 19. Global Hepatitis B Vaccine (Recombinant) Sales Market Share by Company in 2019
Figure 20. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company in 2017
Figure 21. Global Hepatitis B Vaccine (Recombinant) Revenue Market Share by Company in 2019
Figure 22. Global Hepatitis B Vaccine (Recombinant) Sale Price by Company in 2019
Figure 23. Global Hepatitis B Vaccine (Recombinant) Consumption Market Share by Regions 2015-2020
Figure 24. Global Hepatitis B Vaccine (Recombinant) Value Market Share by Regions 2015-2020
Figure 25. Americas Hepatitis B Vaccine (Recombinant) Consumption 2015-2020 (K Units)
Figure 26. Americas Hepatitis B Vaccine (Recombinant) Value 2015-2020 ($ Millions)
Figure 27. APAC Hepatitis B Vaccine (Recombinant) Consumption 2015-2020 (K Units)
Figure 28. APAC Hepatitis B Vaccine (Recombinant) Value 2015-2020 ($ Millions)
Figure 29. Europe Hepatitis B Vaccine (Recombinant) Consumption 2015-2020 (K Units)
Figure 30. Europe Hepatitis B Vaccine (Recombinant) Value 2015-2020 ($ Millions)
Figure 31. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption 2015-2020 (K Units)
Figure 32. Middle East & Africa Hepatitis B Vaccine (Recombinant) Value 2015-2020 ($ Millions)
Figure 33. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries in 2019
Figure 34. Americas Hepatitis B Vaccine (Recombinant) Value Market Share by Countries in 2019
Figure 35. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type in 2019
Figure 36. Americas Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application in 2019
Figure 37. United States Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 38. United States Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 39. Canada Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 40. Canada Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 41. Mexico Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 42. Mexico Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 43. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries in 2019
Figure 44. APAC Hepatitis B Vaccine (Recombinant) Value Market Share by Regions in 2019
Figure 45. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type in 2019
Figure 46. APAC Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application in 2019
Figure 47. China Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 48. China Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 49. Japan Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 50. Japan Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 51. Korea Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 52. Korea Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 53. Southeast Asia Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 54. Southeast Asia Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 55. India Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 56. India Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 57. Australia Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 58. Australia Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 59. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries in 2019
Figure 60. Europe Hepatitis B Vaccine (Recombinant) Value Market Share by Countries in 2019
Figure 61. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type in 2019
Figure 62. Europe Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application in 2019
Figure 63. Germany Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 64. Germany Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 65. France Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 66. France Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 67. UK Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 68. UK Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 69. Italy Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 70. Italy Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 71. Russia Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 72. Russia Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 73. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Countries in 2019
Figure 74. Middle East & Africa Hepatitis B Vaccine (Recombinant) Value Market Share by Countries in 2019
Figure 75. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Type in 2019
Figure 76. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption Market Share by Application in 2019
Figure 77. Egypt Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 78. Egypt Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 79. South Africa Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 80. South Africa Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 81. Israel Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 82. Israel Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 83. Turkey Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 84. Turkey Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 85. GCC Countries Hepatitis B Vaccine (Recombinant) Consumption Growth 2015-2020 (K Units)
Figure 86. GCC Countries Hepatitis B Vaccine (Recombinant) Value Growth 2015-2020 ($ Millions)
Figure 87. Global Hepatitis B Vaccine (Recombinant) Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 88. Global Hepatitis B Vaccine (Recombinant) Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 89. Americas Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 90. Americas Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 91. APAC Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 92. APAC Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 93. Europe Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 94. Europe Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 95. Middle East & Africa Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 96. Middle East & Africa Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 97. United States Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 98. United States Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 99. Canada Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 100. Canada Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 101. Mexico Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 102. Mexico Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 103. Brazil Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 104. Brazil Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 105. China Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 106. China Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 107. Japan Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 108. Japan Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 109. Korea Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 110. Korea Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 111. Southeast Asia Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 112. Southeast Asia Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 113. India Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 114. India Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 115. Australia Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 116. Australia Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 117. Germany Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 118. Germany Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 119. France Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 120. France Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 121. UK Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 122. UK Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 123. Italy Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 124. Italy Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 125. Russia Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 126. Russia Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 127. Spain Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 128. Spain Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 129. Egypt Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 130. Egypt Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 131. South Africa Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 132. South Africa Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 133. Israel Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 134. Israel Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 135. Turkey Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 136. Turkey Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 137. GCC Countries Hepatitis B Vaccine (Recombinant) Consumption 2021-2025 (K Units)
Figure 138. GCC Countries Hepatitis B Vaccine (Recombinant) Value 2021-2025 ($ Millions)
Figure 139. GSK Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 140. Merck Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 141. Dynavax Technologies Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 142. LG Life Sciences Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 143. Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 144. Serum Institute Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 145. KM Biologics Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Figure 146. Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Market Share (2018-2020)
Please feel free to write an email to us or to use our electronic ticketing system.
